Sarcopenia Predicts Prognosis in Patients with Newly Diagnosed Hepatocellular Carcinoma, Independent of Tumor Stage and Liver Function

키워드

참고문헌 (30)

1. Bosy-Westphal A, "Identification of skeletal muscle mass depletion across age and BMI groups in health and disease: there is need for a unified definition", Int J Obes (Lond), 39, pp.379~386 (2015)[DOI]
2. Hanai T, "Sarcopenia impairs prognosis of patients with liver cirrhosis", Nutrition, 31, pp.193~199 (2015)[DOI]
3. Koo HS, "Decreased muscle mass is not an independent risk factor for metabolic syndrome in Korean population aged 70 or older", Clin Endocrinol (Oxf), 82, pp.509~516 (2015)[DOI]
4. Pereira RA, "Sarcopenia in chronic kidney disease on conservative therapy: prevalence and association with mortality", Nephrol Dial Transplant, 30, pp.1718~1725 (2015)[DOI]
5. Bryant RV, "Low muscle mass and sarcopenia: common and predictive of osteopenia in inflammatory bowel disease", Aliment Pharmacol Ther, 41, pp.895~906 (2015)[DOI]
6. Moon JH, "Sarcopenia as a predictor of future cognitive impairment in older adults", J Nutr Health Aging, 20, pp.496~502 (2016)[DOI]
7. Kumar A, "Muscle composition measured by CT scan is a measurable predictor of overall survival in advanced ovarian cancer", Gynecol Oncol, 142, pp.311~316 (2016)[DOI]
8. Shachar SS, "Prognostic value of sarcopenia in adults with solid tumours: a metaanalysis and systematic review", Eur J Cancer, 57, pp.58~67 (2016)[DOI]
9. 박인근, "Prognostic Factors for Risk Stratification of Patients with Recurrent or Metastatic Pancreatic Adenocarcinoma Who Were Treated with Gemcitabine-Based Chemotherapy", Cancer Research and Treatment, 48(4), pp.1264~1273 (2016), 대한암학회
10. Psutka SP, "Decreased skeletal muscle mass is associated with an increased risk of mortality after radical nephrectomy for localized renal cell cancer", J Urol, 195, pp.270~276 (2016)[DOI]
11. Tamandl D, "Markers of sarcopenia quantified by computed tomography predict adverse long-term outcome in patients with resected oesophageal or gastro-oesophageal junction cancer", Eur Radiol, 26, pp.1359~1367 (2016)[DOI]
12. Go SI, "Prognostic impact of sarcopenia in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone", J Cachexia Sarcopenia Muscle, 7, pp.567~576 (2016)[DOI]
13. Dodson RM, "Impact of sarcopenia on outcomes following intra-arterial therapy of hepatic malignancies", J Gastrointest Surg, 17, pp.2123~2132 (2013)[DOI]
14. Imai K, "Skeletal muscle depletion predicts the prognosis of patients with hepatocellular carcinoma treated with sorafenib", Int J Mol Sci, 16, pp.9612~9624 (2015)[DOI]
15. Voron T, "Sarcopenia impacts on short- and long-term results of hepatectomy for hepatocellular carcinoma", Ann Surg, 261, pp.1173~1183 (2015)[DOI]
16. Fujiwara N, "Sarcopenia, intramuscular fat deposition, and visceral adiposity independently predict the outcomes of hepatocellular carcinoma", J Hepatol, 63, pp.131~140 (2015)[DOI]
17. Blauwhoff-Buskermolen S, "Loss of muscle mass during chemotherapy is predictive for poor survival of patients with metastatic colorectal cancer", J Clin Oncol, 34, pp.1339~1344 (2016)[DOI]
18. Malietzis G, "Skeletal muscle changes after elective colorectal cancer resection: a longitudinal study", Ann Surg Oncol, 23, pp.2539~2547 (2016)[DOI]
19. Yoshizumi T, "Abdominal fat: standardized technique for measurement at CT", Radiology, 211, pp.283~286 (1999)[DOI]
20. [URL]
21. Kurth T, "Results of multivariable logistic regression, propensity matching, propensity adjustment, and propensity-based weighting under conditions of nonuniform effect", Am J Epidemiol, 163, pp.262~270 (2006)[DOI]
22. Clark W, "Quantitative measures of visceral adiposity and body mass index in predicting rectal cancer outcomes after neoadjuvant chemoradiation", J Am Coll Surg, 216, pp.1070~1081 (2013)[DOI]
23. Grignol VP, "Increased visceral to subcutaneous fat ratio is associated with decreased overall survival in patients with metastatic melanoma receiving anti-angiogenic therapy", Surg Oncol, 24, pp.353~358 (2015)[DOI]
24. Iwase T, "Impact of body fat distribution on neoadjuvant chemotherapy outcomes in advanced breast cancer patients", Cancer Med, 5, pp.41~48 (2016)[DOI]
25. Okamura A, "Clinical impact of abdominal fat distribution on prognosis after esophagectomy for esophageal squamous cell carcinoma", Ann Surg Oncol, 23, pp.1387~1394 (2016)[DOI]
26. Kaneko G, "Visceral obesity is associated with better recurrencefree survival after curative surgery for Japanese patients with localized clear cell renal cell carcinoma", Jpn J Clin Oncol, 45, pp.210~216 (2015)[DOI]
27. Lee HW, "Prognostic significance of visceral obesity in patients with advanced renal cell carcinoma undergoing nephrectomy", Int J Urol, 22, pp.455~461 (2015)[DOI]
28. Dobs AS, "Effects of enobosarm on muscle wasting and physical function in patients with cancer: a double-blind, randomised controlled phase 2 trial", Lancet Oncol, 14, pp.335~345 (2013)[DOI]
29. Crawford J, "Study design and rationale for the phase 3 clinical development program of enobosarm, a selective androgen receptor modulator, for the prevention and treatment of muscle wasting in cancer patients (POWER Trials)", Curr Oncol Rep, 18, pp.37~ (2016)[DOI]
30. Sinclair M, "Testosterone therapy increases muscle mass in men with cirrhosis and low testosterone: a randomised controlled trial", J Hepatol, 65, pp.906~913 (2016)[DOI]

관련 논문AI추천